Subscribe to our feed.

Symic Biomedical awarded $1.5MM NIH Phase II SBIR grant to develop its proteoglycan mimetic therapeutics to reduce vascular access failures in ESRD

August 26, 2015 — SAN FRANCISCO - Platform therapeutic company Symic Biomedical, Inc. ("Symic") announced today that it has received a $1.5M Phase II SBIR grant from the National Institutes of Health (NIH) to further develop its therapeutic agent to reduce arteriovenous fistula (AVF) failures, a significant unmet clinical need in end stage renal disease (ESRD) patients undergoing hemodialysis. Read More

Purdue researchers report sweet corn could make animal vaccines safer

August 3, 2015 — WEST LAFAYETTE, Ind. - Animal vaccine manufacturers could benefit from the work of two Purdue University researchers who are testing biomaterial made from sweet corn to make vaccines safer. Read More